Journal of Clinical Endocrinology & Metabolism, Vol 75, 1531-1534, Copyright © 1992 by Endocrine Society

ARTICLES

Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism

CJ Rosen and RA Adler
Department of Endocrinology and Metabolism, St. Joseph Hospital, Bangor, Maine 04410.

Hyperthyroidism increases bone turnover, which, in turn, may lead to bone loss from the spine and hip. Treatment of thyrotoxicosis may restore bone mass, but there are few long term prospective studies. We examined lumbar bone mineral density (BMD) in 21 subjects [11 with hyperthyroidism (HT) and 10 controls of similar age] by dual photon absorptiometry in 1986 and by dual energy x-ray densitometry in 1991. All 11 HT patients were successfully treated and remained euthyroid (mean TSH, 2.25 +/- 0.80 mU/L) for more than 3 yr. Lumbar BMD increased 11.03 +/- 2.38% (P < 0.001) in HT patients, but only 2.6 +/- 2.15% (P = 0.10) in control subjects. Among HT patients, the higher the T3 concentration during hyperthyroidism, the greater the subsequent increase in lumbar BMD (r = 0.72; P < 0.03). Age at treatment, in contrast, was not a significant predictor of eventual spinal bone mass. In conclusion, successful treatment of hyperthyroidism produced a significant increase in lumbar BMD. Hence, bone loss associated with thyrotoxicosis may not be permanent. Future work designed to examine the effect of thyroid hormone on skeletal homeostasis should include large scale longitudinal studies of both men and women.

This article has been cited by other articles:

				A. Svare, T. I. L. Nilsen, T. Bjoro, S. Forsmo, B. Schei, and A. Langhammer Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study Eur. J. Endocrinol., November 1, 2009; 161(5): 779 - 786. [Abstract] [Full Text] [PDF]

				B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]

				S. J. Hoffman, J. Vasko-Moser, W. H. Miller, M. W. Lark, M. Gowen, and G. Stroup Rapid Inhibition of Thyroxine-Induced Bone Resorption in the Rat by an Orally Active Vitronectin Receptor Antagonist J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 205 - 211. [Abstract] [Full Text] [PDF]

				M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF]

				L. A. Fitzpatrick Secondary Causes of Osteoporosis Mayo Clin. Proc., May 1, 2002; 77(5): 453 - 468. [Abstract] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				S. L. Greenspan and F. S. Greenspan The Effect of Thyroid Hormone on Skeletal Integrity Ann Intern Med, May 4, 1999; 130(9): 750 - 758. [Abstract] [Full Text] [PDF]

				E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada, J. D. Luna, and N. Olea Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1989 - 1994. [Abstract] [Full Text] [PDF]

				A. Siddiqi, J. M. Burrin, K. Noonan, I. James, D. F. Wood, C. P. Price, and J. P. Monson A Longitudinal Study of Markers of Bone Turnover in Graves' Disease and Their Value in Predicting Bone Mineral Density J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 753 - 759. [Abstract] [Full Text] [PDF]

				L. Wartofsky Thyroid Hormones and Osteoporosis-Reply Arch Intern Med, February 12, 1996; 156(3): 341 - 341. [Abstract] [PDF]